208 related articles for article (PubMed ID: 30720096)
21. Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer.
He T; Zhang Y; Li X; Liu C; Zhu G; Yin X; Zhang Z; Zhao K; Wang Z; Zhao P; Wang K
World J Surg Oncol; 2022 Jun; 20(1):174. PubMed ID: 35650630
[TBL] [Abstract][Full Text] [Related]
22. The Comprehensive Analysis of Hub Gene ARRB2 in Prostate Cancer.
Zhou B; Song H; Xu W; Zhang Y; Liu Y; Qi W
Dis Markers; 2022; 2022():8518378. PubMed ID: 36284990
[TBL] [Abstract][Full Text] [Related]
23. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
[TBL] [Abstract][Full Text] [Related]
24. MTR D919G variant is associated with prostate adenocarcinoma risk: evidence based on 51106 subjects.
Jing HW; Yin L; Yu HY; Zuo L; Liu T
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8329-8340. PubMed ID: 32894539
[TBL] [Abstract][Full Text] [Related]
25. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's Disease as a Risk Factor for Prostate Adenocarcinoma: A Molecular Point of View.
Liu T; Yang Z; Liu S; Wei J
Gerontology; 2023; 69(8):986-1001. PubMed ID: 36921580
[TBL] [Abstract][Full Text] [Related]
27. A Novel Method for Identifying the Potential Cancer Driver Genes Based on Molecular Data Integration.
Zhang W; Wang SL
Biochem Genet; 2020 Feb; 58(1):16-39. PubMed ID: 31115714
[TBL] [Abstract][Full Text] [Related]
28. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
29. An
Lu X; Pan X; Wu CJ; Zhao D; Feng S; Zang Y; Lee R; Khadka S; Amin SB; Jin EJ; Shang X; Deng P; Luo Y; Morgenlander WR; Weinrich J; Lu X; Jiang S; Chang Q; Navone NM; Troncoso P; DePinho RA; Wang YA
Cancer Res; 2018 Jul; 78(14):3823-3833. PubMed ID: 29769196
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.
Ohshima K; Hatakeyama K; Nagashima T; Watanabe Y; Kanto K; Doi Y; Ide T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Serizawa M; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Sci Rep; 2017 Apr; 7(1):641. PubMed ID: 28377632
[TBL] [Abstract][Full Text] [Related]
31. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
[TBL] [Abstract][Full Text] [Related]
32. Twiner: correlation-based regularization for identifying common cancer gene signatures.
Lopes MB; Casimiro S; Vinga S
BMC Bioinformatics; 2019 Jun; 20(1):356. PubMed ID: 31238876
[TBL] [Abstract][Full Text] [Related]
33. Expression patterns and a prognostic model of m
Ou-Yang S; Liu JH; Wang QZ
Biomark Med; 2020 Dec; 14(17):1663-1677. PubMed ID: 33336591
[No Abstract] [Full Text] [Related]
34. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis reveals candidate genes and transcription factors in lung adenocarcinoma.
Chen B; Gao S; Ji C; Song G
Mol Med Rep; 2017 Dec; 16(6):8371-8379. PubMed ID: 28983631
[TBL] [Abstract][Full Text] [Related]
36. VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data.
Jia P; Zhao Z
PLoS Comput Biol; 2014 Feb; 10(2):e1003460. PubMed ID: 24516372
[TBL] [Abstract][Full Text] [Related]
37. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
[TBL] [Abstract][Full Text] [Related]
38. Identification of prostate cancer specific methylation biomarkers from a multi-cancer analysis.
Pu Y; Li C; Yuan H; Wang X
BMC Bioinformatics; 2021 Oct; 22(1):492. PubMed ID: 34641790
[TBL] [Abstract][Full Text] [Related]
39. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
[TBL] [Abstract][Full Text] [Related]
40. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers.
Shi W; Balazs B; Györffy B; Jiang T; Symmans WF; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2014 Apr; 144(3):561-8. PubMed ID: 24619174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
